Biotech News
Paratek Pharmaceuticals Completes Five-Year Microbiologic Surveillance Study of NUZYRA® (omadacycline) Demonstrating No Change in In Vitro Potency Against Indicated Pathogens
- No Emergence of Resistance was Observed - Additional Years of Surveillance are Under Way
BOSTON, July 31, 2024 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc., a biopharmaceutical company focused on providing innovative medical therapies that create positive patient stories in the hospital,...